Bolt Biotherapeutics, Inc. BOLT
Set alert
6.35 USD -0.24 -3.64%
As of Nov 2, 10:36 AM ET
6.35 Day range 6.58
3.10 52-week range 7.78
- YTD
- +16.09%
- 1 year
- +10.24%
- Open
- 6.58
- Prev close
- 6.59
- Mkt cap
- 14.97M
- Vol
- 249.91K
- Avg vol
- 243.87K
- EPS
- -16.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.35
- High
- 6.58
- Forward P/E
- -0.40
- Beta
- 0.92
- Short ratio
- 0.54
- Inst. own
- 58.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 0.60464
- 200-d avg
- 0.795015
- 1y target
- 1.75
3M chart
Signals (24)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Sep 3, 2026 | 2 months ago |
| SMA: Bearish | Sep 2, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 24, 2026 | 2 months ago |
| RSI: Oversold | Aug 13, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
Key statistics
- Market cap
- 19.63M
- Enterprise value
- -30.25M
- Trailing P/E
- 0.00
- Forward P/E
- -0.40
- PEG ratio
- 0.00
- Price / sales
- 1.76
- Price / book
- 0.17
- EPS (TTM)
- -1.71
- Beta
- 0.92
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 11.17M
- Revenue growth
- -11.00%
- Free cash flow
- -33.36M
- Total cash
- 73.70M
- Total debt
- 18.89M
- Return on equity
- -58.04%
- Shares outstanding
- 38.27M
- Short % of float
- 0.22%
- 50-day average
- 0.60464
- 200-day average
- 0.795015
Analyst view
Consensus: none
Price target (mean) 1.75 -72.4% downside
Now 6.35
- Target (low)
- 1.50
- Target (mean)
- 1.75
- Target (high)
- 2.00
Ratings (0m) 4 0 buy · 4 hold · 0 sell
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.35.
Financials — quick view
BOLT Revenue — quarterly 5.00K
BOLT Net income — quarterly -7.72M
BOLT EPS — quarterly -4.57
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.36 | -0.40 | -0.04 | -11.11% |
| Aug 13, 2024 | Jun 1, 2024 | -0.54 | -0.56 | -0.02 | -3.70% |
| Aug 13, 2024 | Jun 1, 2024 | -0.54 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.51 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.51 | -0.28 | +0.23 | +45.10% |
| Mar 21, 2024 | Dec 1, 2023 | -0.47 | -0.47 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Aug 15, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| May 15, 2024 | Leerink Partners | down | Outperform | Market Perform |
| May 15, 2024 | Jones Trading | down | Buy | Hold |
| May 15, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| May 15, 2024 | Guggenheim | down | Buy | Neutral |
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- boltbio.com
News
- Bolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks Transcript
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT)
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Bolt’s Acquisition Positions It To Advance Prana’s Inspire Multispecific Antibody Pipeline; Phase 2 PRA-216 Readouts Expected Starting Q2 2027
- Bolt Biotherapeutics Secures $120M Private Placement, With Potential Additional $60M From Warrant Exercise To Fund Operations Into 2028
- Bolt Biotherapeutics Acquires Prana Therapies In Sign-And-Close Reverse Merger, Shifts Focus To Multispecific Antibody Pipeline; Prana Holders to Own 51.7% of Combined Company, Backed by Up To $180M Financing
- Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications
- Bolt Biotherapeutics (NASDAQ:BOLT) Share Price Breaks Above Two Hundred Day Moving Average – Time to Sell?
- Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Crosses Below 200-Day Moving Average – Should You Sell?
- Bolt Biotherapeutics (NASDAQ:BOLT) VP Sarah Nemec Sells 4,077 Shares
Your note
Sign in to keep a note on BOLT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ENGLEMAN EDGAR G. M.D. | Director | Sale | Nov 29, 2023 | 0 |
| PEREZ EDITH A | Officer | Purchase | Dec 5, 2023 | 46,612 |
| QUINN WILLIAM P | Chief Financial Officer | Purchase | Dec 11, 2023 | 36,272 |
| VIVO CAPITAL VIII, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 20, 2023 | 0 |
| YONEHIRO GRANT | Officer | Purchase | Dec 5, 2023 | 8,918 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tang Capital Management, LLC | 9.96% | 3,812,773 | 1.96M | Sep 29, 2024 |
| Vivo Capital, LLC | 9.20% | 3,521,291 | 1.81M | Sep 29, 2024 |
| Sofinnova Investments, Inc. | 7.20% | 2,754,437 | 1.41M | Sep 29, 2024 |
| Pivotal bioVenture Partners Investment Advisor, LLC | 4.94% | 1,891,467 | 969.94K | Sep 29, 2024 |
| Nan Fung Group Holdings Limited | 3.05% | 1,166,952 | 598.41K | Sep 29, 2024 |
| Vanguard Group Inc | 2.79% | 1,067,405 | 547.37K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.25% | 861,868 | 441.96K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.54% | 205,537 | 105.40K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 146,652 | 75.20K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.28% | 107,906 | 55.33K | Oct 30, 2024 |
| Fidelity Enhanced Small Cap ETF | 0.21% | 82,000 | 42.05K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.18% | 70,159 | 35.98K | Oct 30, 2024 |